Biogen (BIIB)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$205.70-1.32%
Close 2026-07-07 · 1-day change
Reading BIIB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BIIB free→NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading BIIB? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BIIB free→QuarterlyIQ Insights · BIIB
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $205.70. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $206 BIIB trades at 13× p/e, below its 22× p/e peer median. Our $280 fair value sits well above the price. We hold it with low confidence: our number sits above the analyst range and the peer anchor overstates how cheap it looks. Analysts target $157–$260. Note: our $280 fair value sits above the entire analyst range ($157–$260). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $223.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $496.72 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $555.82 | — | — | Hist. CAGR | high |
| graham number | 12M | $211.65 | — | — | TTM | high |
| Mgmt guidance |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$157.00 – $260.00 (median $223.00) · 14 analysts · as of 2026-07-07
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $320.26 |
| 21.7 |
| 14.75 |
| Mgmt |
| high |
| Peer EV/EBITDA | 12M | $255.92 | 14.7 | 18.69 | TTM | high |
| Peer P/FCF | 12M | $343.29 | 20.9 | 16.39 | TTM | high |
| Peer P/E | 12M | $343.93 | 21.7 | 15.84 | TTM | high |
| Peer P/S | 12M | $678.51 | 10.1 | 66.96 | TTM | high |
| PEG | 12M | $35.87 | 2.3 | 15.84 | TTM | high |
| residual income | 12M | $141.58 | — | — | TTM | high |
| Own P/E history | 12M | $198.66 | 12.5 | 15.84 | TTM | high |
| triangulated | 12M | $359.16 | 21.7 | 16.54 | Triangulated | high |
| Mgmt guidance | 3Y | $353.22 | 21.7 | 16.27 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $522.10 | 20.9 | 24.93 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $365.02 | 21.7 | 16.81 | Analyst | medium |
| Peer P/S | 3Y | $716.75 | 10.1 | 70.74 | guidance | medium |
| PEG | 3Y | $38.06 | 2.3 | 16.81 | Analyst | medium |
| Own P/E history | 3Y | $210.84 | 12.5 | 16.81 | Analyst | medium |
| Mgmt guidance | 5Y | $377.05 | 21.7 | 17.37 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $690.47 | 20.9 | 32.97 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $370.19 | 21.7 | 17.05 | Analyst | high |
| Peer P/S | 5Y | $726.90 | 10.1 | 71.74 | guidance | high |
| PEG | 5Y | $38.60 | 2.3 | 17.05 | Analyst | high |
| Own P/E history | 5Y | $213.82 | 12.5 | 17.05 | Analyst | high |